Table 5.

Differences in CGI and CGA scores in the treatment-resistant and control groups observed after 12 weeks of treatment.

Treatment-Resistant ASD Subjects (N = 42) (with Pharmacogenetic Intervention)
Improvement in CGI scores (basal–final scores)	2.26 ± 1.55
Improvement in CGA scores (final–basal scores)	20.29 ± 11.85
Control subjects (N = 62)
Improvement in CGI scores (basal–final scores)	−0.87 ± 9.44
Improvement in CGA scores (final–basal scores)	6.59 ± 7.76
Non-Responders (N = 21) (no improvement in CGI or CGA scores)
Improvement in CGI scores (basal–final scores)	0.10 ± 0.63
Improvement in CGA scores (final–basal scores)	0.48 ± 2.18
Responders (N = 41) (Improvement in CGI and CGA scores)
Improvement in CGI scores (basal-final scores)	1.54 ± 0.588
Improvement in CGA scores (final-basal scores)	11.74 ± 7.17